Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Zhejiang Huahai
Pharma
Generic tariffs, Samsung Bio, HK IPO—Fierce Pharma Asia
President Trump unveiled generic drug tariffs. Samsung Bio will buy PolyPepide for $1.8 billion. A U.S. biotech seeks an IPO first in Hong Kong.
Angus Liu
Jul 24, 2026 9:00am
Huahai poaches quality chief from Hengrui amid FDA citations
Jul 16, 2026 4:11pm
Merck, Sinopharm agree on deal for China rights to Lagevrio
Sep 28, 2022 11:36am
Takeda, Eisai, US-China audit deal—Fierce Pharma Asia
Aug 26, 2022 10:10am
Pfizer tabs controversial Chinese firm Huahai to make Paxlovid
Aug 23, 2022 3:36pm
Biocon-Viatris, AstraZeneca, Huhai and more—Fierce Pharma Asia
Nov 19, 2021 8:20am
